Literature DB >> 24449819

Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial.

Viky Y Suncion1, Eduard Ghersin, Joel E Fishman, Juan Pablo Zambrano, Vasileios Karantalis, Nicole Mandel, Katarina H Nelson, Gary Gerstenblith, Darcy L DiFede Velazquez, Elayne Breton, Kranthi Sitammagari, Ivonne H Schulman, Sabrina N Taldone, Adam R Williams, Cristina Sanina, Peter V Johnston, Jeffrey Brinker, Peter Altman, Muzammil Mushtaq, Barry Trachtenberg, Adam M Mendizabal, Melissa Tracy, Jose Da Silva, Ian K McNiece, Alberto C Lardo, Richard T George, Joshua M Hare, Alan W Heldman.   

Abstract

RATIONALE: Transendocardial stem cell injection (TESI) with mesenchymal stem cells improves remodeling in chronic ischemic cardiomyopathy, but the effect of the injection site remains unknown.
OBJECTIVE: To address whether TESI exerts its effects at the site of injection only or also in remote areas, we hypothesized that segmental myocardial scar and segmental ejection fraction improve to a greater extent in injected than in noninjected segments. METHODS AND
RESULTS: Biplane ventriculographic and endocardial tracings were recorded. TESI was guided to 10 sites in infarct-border zones. Sites were mapped according to the 17-myocardial segment model. As a result, 510 segments were analyzed in 30 patients before and 13 months after TESI. Segmental early enhancement defect (a measure of scar size) was reduced by TESI in both injected (-43.7 ± 4.4%; n=95; P<0.01) and noninjected segments (-25.1 ± 7.8%; n=148; P<0.001; between-group comparison P<0.05). Conversely, segmental ejection fraction (a measure of contractile performance) improved in injected scar segments (19.9 ± 3.3-26.3 ± 3.5%; P=0.003) but not in noninjected scar segments (21.3 ± 2.6-23.5 ± 3.2%; P=0.20; between-group comparison P<0.05). Furthermore, segmental ejection fraction in injected scar segments improved to a greater degree in patients with baseline segmental ejection fraction <20% (12.1 ± 1.2-19.9 ± 2.7%; n=18; P=0.003), versus <20% (31.7 ± 3.4-35.5 ± 3.3%; n=12; P=0.33, between-group comparison P<0.0001).
CONCLUSIONS: These findings illustrate a dichotomy in regional responses to TESI. Although scar size reduction was evident in all scar segments, scar size reduction and ventricular functional responses preferentially occurred at the sites of TESI versus non-TESI sites. Furthermore, improvement was greatest when segmental left ventricular dysfunction was severe.

Entities:  

Keywords:  cells; magnetic resonance imaging; myocardial infarction; tomography

Mesh:

Year:  2014        PMID: 24449819      PMCID: PMC4067050          DOI: 10.1161/CIRCRESAHA.114.302854

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  35 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scar.

Authors:  Albert C Lardo; Marco A S Cordeiro; Caterina Silva; Luciano C Amado; Richard T George; Anastasios P Saliaris; Karl H Schuleri; Veronica R Fernandes; Menekhem Zviman; Saman Nazarian; Henry R Halperin; Katherine C Wu; Joshua M Hare; Joao A C Lima
Journal:  Circulation       Date:  2006-01-24       Impact factor: 29.690

3.  Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

Authors:  Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare
Journal:  Circ Res       Date:  2010-07-29       Impact factor: 17.367

Review 4.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.

Authors:  Adam R Williams; Joshua M Hare
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

5.  Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling.

Authors:  Adam R Williams; Barry Trachtenberg; Darcy L Velazquez; Ian McNiece; Peter Altman; Didier Rouy; Adam M Mendizabal; Pradip M Pattany; Gustavo A Lopera; Joel Fishman; Juan P Zambrano; Alan W Heldman; Joshua M Hare
Journal:  Circ Res       Date:  2011-03-17       Impact factor: 17.367

6.  Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction.

Authors:  Adam R Williams; Konstantinos E Hatzistergos; Benjamin Addicott; Fred McCall; Decio Carvalho; Viky Suncion; Azorides R Morales; Jose Da Silva; Mark A Sussman; Alan W Heldman; Joshua M Hare
Journal:  Circulation       Date:  2012-12-05       Impact factor: 29.690

7.  S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells.

Authors:  Samirah A Gomes; Erika B Rangel; Courtney Premer; Raul A Dulce; Yenong Cao; Victoria Florea; Wayne Balkan; Claudia O Rodrigues; Andrew V Schally; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-03       Impact factor: 11.205

Review 8.  Paracrine mechanisms in adult stem cell signaling and therapy.

Authors:  Massimiliano Gnecchi; Zhiping Zhang; Aiguo Ni; Victor J Dzau
Journal:  Circ Res       Date:  2008-11-21       Impact factor: 17.367

9.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Authors:  Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

10.  Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling.

Authors:  Adam R Williams; Viky Y Suncion; Frederic McCall; Danny Guerra; Jacques Mather; Juan P Zambrano; Alan W Heldman; Joshua M Hare
Journal:  J Am Heart Assoc       Date:  2013-05-17       Impact factor: 5.501

View more
  50 in total

Review 1.  Recent Developments in Heart Failure.

Authors:  Sujith Dassanayaka; Steven P Jones
Journal:  Circ Res       Date:  2015-09-11       Impact factor: 17.367

2.  A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1.

Authors:  Shaurya Joshi; Jianqin Wei; Nanette H Bishopric
Journal:  Biochim Biophys Acta       Date:  2015-12-02

3.  Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial.

Authors:  Vasileios Karantalis; Darcy L DiFede; Gary Gerstenblith; Si Pham; James Symes; Juan Pablo Zambrano; Joel Fishman; Pradip Pattany; Ian McNiece; John Conte; Steven Schulman; Katherine Wu; Ashish Shah; Elayne Breton; Janice Davis-Sproul; Richard Schwarz; Gary Feigenbaum; Muzammil Mushtaq; Viky Y Suncion; Albert C Lardo; Ivan Borrello; Adam Mendizabal; Tomer Z Karas; John Byrnes; Maureen Lowery; Alan W Heldman; Joshua M Hare
Journal:  Circ Res       Date:  2014-02-24       Impact factor: 17.367

4.  Clinical research skills development program in cell-based regenerative medicine.

Authors:  Ivonne Hernandez Schulman; Viky Suncion; Vasileios Karantalis; Wayne Balkan; Joshua M Hare
Journal:  Stem Cells Transl Med       Date:  2014-12-29       Impact factor: 6.940

Review 5.  Programming and reprogramming a human heart cell.

Authors:  Makoto Sahara; Federica Santoro; Kenneth R Chien
Journal:  EMBO J       Date:  2015-02-20       Impact factor: 11.598

Review 6.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

Review 7.  Use of mesenchymal stem cells for therapy of cardiac disease.

Authors:  Vasileios Karantalis; Joshua M Hare
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

8.  Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival.

Authors:  Victoria Florea; Sonia S Majid; Rosemeire M Kanashiro-Takeuchi; Ren-Zhi Cai; Norman L Block; Andrew V Schally; Joshua M Hare; Claudia O Rodrigues
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

9.  A cardiac patch from aligned microvessel and cardiomyocyte patches.

Authors:  Jeremy A Schaefer; Pilar A Guzman; Sonja B Riemenschneider; Timothy J Kamp; Robert T Tranquillo
Journal:  J Tissue Eng Regen Med       Date:  2017-11-23       Impact factor: 3.963

10.  Improved conduction and increased cell retention in healed MI using mesenchymal stem cells suspended in alginate hydrogel.

Authors:  Nikhil C Panda; Sean T Zuckerman; Olurotimi O Mesubi; David S Rosenbaum; Marc S Penn; J Kevin Donahue; Eben Alsberg; Kenneth R Laurita
Journal:  J Interv Card Electrophysiol       Date:  2014-09-19       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.